Human natural killer cells in major histocompatibility complex class I deficiency.

We read with interest the personal reflection of. Hans-Gustaf Ljunggren from the Karolinska Institute (KI) about the path towards natural killer (NK) cell-based cancer immunotherapy.(1) The manuscript includes a paragraph about mouse major histocompatibility complex (MHC) class I deficiency, and as we published several papers about the equivalent entity, Human Leukocyte Antigen (HLA) class I defects, we were inspired to briefly remind the NK cell status in these diseases.